With Its Stock Down Over 50%, What’s Next for UnitedHealth?

UnitedHealth's stock has declined over 50% due to a Q1 earnings miss attributed to surging medical utilization, the withdrawal of 2025 guidance, a CEO change, and a Wall Street Journal report of a criminal probe into its Medicare Advantage practices. The company faces increased regulatory scrutiny regarding risk assessments in its Medicare Advantage program, potentially leading to clawbacks of overpayments and reduced margins. Despite these challenges, Morningstar analysts believe the stock is moderately undervalued, citing long-term growth opportunities in healthcare spending, though near-term earnings growth will likely be impacted.

Analysis

UnitedHealth Group (UNH) has experienced a substantial share price decline, falling over 50% from its November 2024 peak of $630 per share to approximately $300. This downturn is attributed to several critical factors: a significant Q1 earnings miss, the first in over a decade, driven by unexpectedly high medical utilization; the subsequent withdrawal of its 2025 earnings guidance; and the abrupt resignation of CEO Andrew Witty, who has been succeeded by former CEO and current board chair Stephen Hemsley. Further pressure stems from a Wall Street Journal report detailing a criminal probe into UNH's Medicare Advantage (MA) program practices. The company, the largest MA insurer with nearly 30% market share, faces intensified regulatory scrutiny, highlighted by a Centers for Medicare & Medicaid Services (CMS) decision to increase its MA auditing staff from 40 to 2,000. An Office of the Inspector General (OIG) report also found that UNH accounted for roughly 50% of MA overpayments, disproportionate to its market share, raising concerns about potential clawbacks and future margin compression in this key segment. Consequently, Morningstar has raised its Uncertainty Rating for UNH to High and revised its Fair Value Estimate to $473.00. While UNH operates a diversified model encompassing medical insurance, pharmacy benefits (OptumRx), and healthcare delivery and analytics (Optum Health), the current challenges primarily impact its core insurance profitability and regulatory standing. The reinstatement of Stephen Hemsley, a seasoned executive with considerable shareholdings, is seen as a move to stabilize the company and navigate crucial MA plan design adjustments due in early June.

Key Decisions for Investors

• Investors should recognize the significant near-term headwinds facing UnitedHealth, including heightened regulatory scrutiny over its Medicare Advantage business, ongoing pressures from increased medical utilization, and the recent leadership transition, all contributing to Morningstar's High Uncertainty Rating.
• Despite the stock trading considerably below Morningstar's Fair Value Estimate of $473.00, suggesting potential undervaluation for long-term investors tolerant of high risk, a cautious stance is advisable given the severity of current challenges and the possibility of further negative developments.
• Key developments to monitor closely include the upcoming Medicare Advantage plan design submissions in early June, official outcomes or disclosures regarding regulatory investigations, and the strategic initiatives undertaken by new CEO Stephen Hemsley to address profitability and rebuild investor confidence before committing new capital.